Overcoming innate immune barriers that impede AAV gene therapy vectors
Open accessThe DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Abstract
The field of gene therapy has made considerable progress over the past several years. Adeno-associated virus (AAV) vectors have emerged as promising and attractive tools for in vivo gene therapy. Despite the recent clinical successes achieved with recombinant AAVs (rAAVs) for therapeutics, host immune responses against the vector and transgene product have been observed in numerous preclinical and clinical studies. These outcomes have hampered the advancement of AAV gene therapies, preventing them from becoming fully viable and safe medicines. The human immune system is multidimensional and complex. Both the innate and adaptive arms of the immune system seem to play a concerted role in the response against rAAVs. While most efforts have been focused on the role of adaptive immunity and developing ways to overcome it, the innate immune system has also been found to have a critical function. Innate immunity not only mediates the initial response to the vector, but also primes the adaptive immune system to launch a more deleterious attack against the foreign vector. This Review highlights what is known about innate immune responses against rAAVs and discusses potential strategies to circumvent these pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“further supported with the reports of complement-mediated TMA cases in subjects receiving high doses of systemic AAV (40, 41)”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the goal of commonly used immunomodulation regimes was to inhibit T cell function and included mostly corticosteroids, sirolimus, tacrolimus, mycophenolate mofetil, or cyclosporine (40, 41).”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, rAAV capsid-targeting TLR2, various DNA sensors, and complement activation may also play a role (22).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304 · cited 2×
“Figure 1, activated IRAKs lead to transcription of several proinflammatory cytokines, including TNF-α and IL-6 (35).”
BackgroundPattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895 · cited 1×
“These signals lead to the expression of host defense genes, like the MHC genes, proinflammatory cytokines, chemokines, and type I and III IFNs (31).”
BackgroundCyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity
Kawai, T., & Akira, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.006 · Cited by 3,658 · cited 1×
“TLRs that have been implicated in initiating inflammatory responses to viruses are TLR2 (glycoproteins and lipoproteins), TLR3 (dsRNA), TLR4 (glycoproteins and bacterial LPS), TLR7 (ssRNA), TLR8 (ssRNA), and TLR9 (unmethylated CpG [cytosine-phosphate-guanine] DNA) (39).”
BackgroundRegulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297 · cited 2×
“Secreted cytokines and chemokines are also critical for inducing effective adaptive and memory immune responses (33).”
BackgroundToll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233 · cited 4×
“TLR1, 2, 4, 5, 6, and 10 (glycoprotein-recognizing receptors) are commonly located on the cell surface, whereas TLR3, 7, 8, and 9 (nucleic acid–specific receptors) are generally found on the endosomal membrane (38).”
BackgroundInfluentialSTING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · cited 1×
“Mice deficient in cGAS and STING are more susceptible to lethal herpes simplex virus 1 (HSV1) infection because of a decrease in type I IFN response (71, 72).”
BackgroundIKKε and TBK1 are essential components of the IRF3 signaling pathway
Fitzgerald, K. A., McWhirter, S. M., Faia, K. L., Rowe, D. C., Latz, E., Golenbock, D. T., Coyle, A. J., Liao, S.-M., & Maniatis, T. (2003) · Nature Immunology · doi:10.1038/ni921 · Cited by 2,676
Self-citationAIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC
Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D. R., Latz, E., & Fitzgerald, K. A. (2009) · Nature · doi:10.1038/nature07725 · Cited by 2,627 · cited 14×
“Further studies are required to elucidate whether AAV infection activates the AIM2 inflammasome pathway.”
BackgroundInfluentialSelf-citationAdeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Self-citation
Research works printed but not linked: 6
- Audentes therapeutics provides update on the ASPIRO clinical trial evaluating AT132 in patients with X-linked myotubular myopathy. Press release. Audentes Therapeutics. August 20, 2020. https://www.audentestx.com/press_release/audentes-therapeutics-provides-update-on-the-aspiro-clinical-trial-evaluating-at132-in-patients-with-x-linked-myotubular-myopathy/ Accessed November 2, 2020
- Pfizer’s new phase 1b results of gene therapy in ambulatory boys with duchenne muscular dystrophy (DMD) support advancement into pivotal phase 3 study. Press release. Pfizer. May 15, 2020. https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizers-New-Phase-1b-Results-of-Gene-Therapy-in-Ambulatory-Boys-with-Duchenne-Muscular-Dystrophy-DMD-Support-Advancement-into-Pivotal-Phase-3-Study/default.aspx Accessed November 2, 2020
- Chan, 2019, Reducing AAV-mediated immune responses and pathology in a subretinal pig model by engineering the vector genome, Mol Ther, 27
- Letizia, 2019, Engineering AAV vectors to reduce CD8+ T cell responses following intramuscular injection in mice, Mol Ther, 27
- Pfizer presents initial clinical data on phase 1b gene therapy study for duchenne muscular dystrophy (DMD). Press release. Pfizer. June 28, 2019. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_initial_clinical_data_on_phase_1b_gene_therapy_study_for_duchenne_muscular_dystrophy_dmd Accessed November 2, 2020
- Solid Biosciences provides SGT-001 program update. Press release. Solid Biosciences. November 12, 2019. https://www.solidbio.com/about/media/press-releases/solid-biosciences-provides-sgt-001-program-update Accessed November 2, 2020
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Self-citationTabebordbar, M., Lagerborg, K. A., Stanton, A., King, E. M., Ye, S., Tellez, L., Krunnfusz, A., Tavakoli, S., Widrick, J. J., Messemer, K. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.028 · Cited by 506
“These two attributes suggest that this class of AAV capsids could lower the dose of virus needed to achieve therapeutic levels of target cell transduction, lessening therapy-related risk for classical activation of complement by capsid/antibody complexes (Muhuri et al., 2021) andmitigating potentially detrimental cons…”
AAV-based in vivo gene therapy for neurological disorders
Ling, Q., Herstine, J. A., Bradbury, A., & Gray, S. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00766-7 · Cited by 197
“A comprehensive summary of the pharmacological approaches to minimize immune responses against AAV can be found in a recent review 92 .”
BackgroundrAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
“This situation is further exacerbated by the fact that repeated dosing is challenging due to immune responses against AAV (8).”
BackgroundAddressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’
Kishimoto, T. K., & Samulski, R. J. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2060737 · Cited by 152
Salabarria, S. M., Corti, M., Coleman, K. E., Wichman, M. B., Berthy, J. A., D’Souza, P., Tifft, C. J., Herzog, R. W., Elder, M. E., Shoemaker, L. R., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173510 · Cited by 159
“…AAV are recognized via the adaptor proteins, Toll-like receptors (TLRs), primarily TLR2 and TLR9, which can trigger an innate immune response and promote the activation of adaptive immunity through activation of cytokines and interferons (IFNs) that in turn activate CD8 + T cells (8, 12, 14, 15).”
BackgroundDurability of transgene expression after rAAV gene therapy
Muhuri, M., Lévy, D., Schulz, M., McCarty, D. M., & Gao, G. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.03.004 · Cited by 172
Self-citationNovel vectors and approaches for gene therapy in liver diseases
Maestro, S., Weber, N. D., Zabaleta, N., Aldabe, R., & González‐Aseguinolaza, G. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100300 · Cited by 159
“option already successfully applied in both preclinical and clinical trials is the administration of immunosuppressive treatments.(137,139,140) However, all carry the associated risk of leaving the patient transiently immunocompromised and thus exposed to infection, and depending on the characteristics of the disease,…”
BackgroundAAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
“An overview on immunosuppressive medications used to mitigate immune responses to AAV therapies in clinical or nonclinical studies is given in Table 4.(35,41,134,135) Immunomodulatory drugs are often given in combination to achieve optimal reduction of the immune response.”
BackgroundUnderstanding AAV vector immunogenicity: from particle to patient
Dhungel, B. P., Winburn, I. C., Pereira, C. D. F., Huang, K., Chhabra, A., & Rasko, J. E. J. (2024) · Theranostics · doi:10.7150/thno.89380 · Cited by 101
“As complement is an important modulator of the anti-AAV immune response, inhibiting the complement pathway could help mitigate anti-AAV immune responses [76].”
BackgroundSmith, C. J., Ross, N., Kamal, A., Kim, K. Y., Kropf, E., Deschatelets, P., Francois, C., Quinn, W. J., Singh, I., Majowicz, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.999021 · Cited by 86
“More recent work has highlighted the role of innate immune system in response to AAV therapeutics (42–46) further supported with the reports of complement-mediated TMA cases in subjects receiving high doses of systemic AAV (40, 41) Here, using human blood in vitro, we demonstrate that complement and pre-existing AAV n…”
ResultMonahan, P. E., Négrier, C., Tarantino, M., Valentino, L. A., & Mingozzi, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112471 · Cited by 85
“Early clinical trial data support the role of innate immunity in AAV immunogenicity [5,30,82].”
BackgroundPrasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81
“1B).(43,44) Considering recently reported adverse events, the U.”
BackgroundGene therapy for liver diseases — progress and challenges
Zabaleta, N., Unzu, C., Weber, N. D., & González‐Aseguinolaza, G. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00729-0 · Cited by 80
A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders
Vrellaku, B., Hassan, I. S., Howitt, R., Webster, C. P., Harriss, E., McBlane, F., Betts, C., Schettini, J. L., Lion, M., Mindur, J. E., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.016 · Cited by 84
Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
“• suppression of ITR promoter activity (70)”
BackgroundImmunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
“Furthermore, rAAV capsid-targeting TLR2, various DNA sensors, and complement activation may also play a role (22).”
BackgroundInnate Immune Response to Viral Vectors in Gene Therapy
Wang, Y., & Shao, W. (2023) · Viruses · doi:10.3390/v15091801 · Cited by 67
“It is pertinent to mention that double-stranded RNA molecules are duly recognized by MDA5 and RIG-I, subsequently instigating the production of IFN-β [13].”
BackgroundInfluentialBurdett, T., & Nuseibeh, S. (2022) · Gene Therapy · doi:10.1038/s41434-022-00363-0 · Cited by 61
“As well as issues with immunogenicity at the innate level [30, 31], the use of rAAV vectors in gene therapy is exacerbated by the high prevalence of AAV neutralising antibodies (NAbs) in human populations due to the widespread transmission of wild-type AAV.”
BackgroundMuhuri, M., Zhan, W., Maeda, Y., Li, J., Lotun, A., Chen, J., Sylvia, K., Dasgupta, I., Arjomandnejad, M., Nixon, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674242 · Cited by 50
Self-citationWang, J.-H., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.017 · Cited by 53
Self-citationRode, L., Bär, C., Groß, S., Rossi, A., Meumann, N., Viereck, J., Abbas, N., Xiao, K., Riedel, I., Gietz, A., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.003 · Cited by 48
Talifu, Z., Li, J., Pan, Y., Ke, H., Zhang, C.-J., Xu, X., Gao, F., Yu, Y. H., Du, L.-J., & Li, J.-J. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.353482 · Cited by 58
“In addition, development of viral vector technologies such as adenoassociated viruses (AAVs) and retroviruses, and new theoretical and experimental methods, have enabled rapid advances in the field of cell reprogramming (Verdera et al., 2020; Muhuri et al., 2021).”
BackgroundGuo, Y., Chen, J., Ji, W., Xu, L., Xie, Y., He, S., Lai, C., Hou, K., Li, Z., Chen, G., et al. (2023) · Molecular Therapy Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.021 · Cited by 47
Greer-Short, A., Greenwood, A., Leon, E. C., Qureshi, T. N., von Kraut, K., Wong, J., Tsui, J. H., Reid, C. A., Cheng, Z., Easter, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57481-7 · Cited by 62
Smith, T. J., Elmore, Z. C., Fusco, R. M., Hull, J. A., Rosales, A., Martinez, M. L., Tarantal, A. F., & Asokan, A. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.004 · Cited by 45
Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial
Davies, J. C., Polineni, D., Boyd, A. C., Donaldson, S. H., Gill, D. R., Griesenbach, U., Hyde, S. C., Jain, R., McLachlan, G., Mall, M. A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202402-0389ci · Cited by 49
“Furthermore, ef fi cacy of AAVs can be impacted by preexisting immunity as well as adaptive immune responses after vector administration (51, 52).”
The curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 52
Self-citationGene therapy for monogenic disorders: challenges, strategies, and perspectives
Zhang, Y., & Wu, Z. (2023) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2023.08.001 · Cited by 46
Methods and Limitations of Augmenting Mesenchymal Stem Cells for Therapeutic Applications
Huerta, C. T., Ortiz, Y. Y., Liu, Z., & Velazquez, O. C. (2022) · Advances in Wound Care · doi:10.1089/wound.2022.0107 · Cited by 41
“40,41”
Adeno-associated virus vectors and neurotoxicity—lessons from preclinical and human studies
Stone, D., Aubert, M., & Jerome, K. R. (2023) · Gene Therapy · doi:10.1038/s41434-023-00405-1 · Cited by 44
“Host innate and transgene-or capsid-speci fi c adaptive immune responses initiated after administration of AAV vectors play a role in therapy-related toxicity in multiple species and are reviewed in detail elsewhere [65 – 67].”
Wada, M., Uchida, N., Posadas-Herrera, G., Hayashita‐Kinoh, H., Tsunekawa, Y., Hirai, Y., & Okada, T. (2023) · Gene Therapy · doi:10.1038/s41434-023-00398-x · Cited by 44
“low-dose administration of the AAV5 vector resulted in no elevation of liver enzymes, minimal T-cell activation, and sustained coagulation factor activity among most patients in a hemophilia gene therapy [9, 32].”
BackgroundZhao, Z., Kim, J., Suja, V. C., Kapate, N., Gao, Y., Guo, J., Muzykantov, V. R., & Mitragotri, S. (2022) · Advanced Science · doi:10.1002/advs.202201293 · Cited by 36
Kachanov, A., Kostyusheva, A. P., Brezgin, S. A., Karandashov, I. V., Ponomareva, N. I., Tikhonov, A., Lukashev, A. N., Pokrovsky, V. S., Zamyatnin, A. A., Parodi, A., et al. (2024) · Medicinal Research Reviews · doi:10.1002/med.22036 · Cited by 49
Progress of nanoparticle drug delivery system for the treatment of glioma
Lai, G., Wu, H., Yang, K., Hu, K., Yan, Z., Chen, X., Fu, F., Li, J., Xie, G., Wang, H., et al. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1403511 · Cited by 40
“However, serious adverse effects, including rare cases of treatment-related mortality (Bulcha et al., 2021), can occur owing to immunogenicity (Hamilton and Wright, 2021; Muhuri et al., 2021).”
BackgroundGene therapy for genetic diseases: challenges and future directions
Beibei, Q. I. E., Tuo, J., Chen, F., Ding, H., & Lyu, L. (2025) · MedComm · doi:10.1002/mco2.70091 · Cited by 45
Modifying immune responses to adeno-associated virus vectors by capsid engineering
Bentler, M., Hardet, R., Ertelt, M., Rudolf, D., Kaniowska, D., Schneider, A., Vondran, F. W. R., Schoeder, C. T., Delphin, M., Lucifora, J., et al. (2023) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.015 · Cited by 34
“Occurrence of acute thrombocytopenia or hepatic or renal toxicity is also correlated with high vector doses.(6,7) Consequently, patients are closely monitored, and immunosuppressive drugs are administered.”
BackgroundPeptide ligands for the affinity purification of adeno‐associated viruses from HEK 293 cell lysates
Chu, W., Shastry, S., Barbieri, E., Prodromou, R., Greback‐Clarke, P., Smith, W. K., Moore, B., Kilgore, R., Cummings, C., Pancorbo, J., et al. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28495 · Cited by 35
“been introduced, which feature improved gene packing and tissue tropism as well as lower immunogenicity and hepatotoxicity (Muhuri et al., 2021).”
BackgroundGene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway
Dreismann, A. K., Hallam, T. M., Tam, L. C. S., Nguyen, C. V., Hughes, J. P., Ellis, S., & Harris, C. L. (2022) · Immunological Reviews · doi:10.1111/imr.13149 · Cited by 36
Zhang, P., Hu, X., Li, Z., Liu, Q., Liu, L., Jin, Y.-Y., Liu, S., Zhao, X., Wang, J., Hao, D., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adj5465 · Cited by 39
“S10, D to F), aligning with prior in vivo observations that AAVs mount a high immune response in a dose-dependent manner ( 37 , 38 ).”
BackgroundZhan, W., Muhuri, M., Tai, P. W. L., & Gao, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673699 · Cited by 37
“Innate immunity against rAAVs is remarkably subdued as compared to other viral vectors, but the transgene cargo can be recognized by various pattern-recognition receptors (PRRs) (61).”
BackgroundSelf-citationOrganoids and microphysiological systems: Promising models for accelerating AAV gene therapy studies
Ramamurthy, R. M., Atala, A., Porada, C. D., & Almeida-Porada, G. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011143 · Cited by 36
Linthout, S. V., Stellos, K., Giacca, M., Bertero, E., Cannata, A. N., Carrier, L., García‐Pavía, P., Ghigo, A., González, A., Haugaa, K. H., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3516 · Cited by 33
Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders
Davidson, B. L., Gao, G., Berry‐Kravis, E., Bradbury, A. M., Bönnemann, C. G., Buxbaum, J. D., Corcoran, G. R., Gray, S. J., Gray‐Edwards, H. L., Kleiman, R. J., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.014 · Cited by 31
“30 No 7 July 2022 tent, which enhances transgene stability by reducing immunogenicity.(50,51) Where possible, the availability of relevant pre-clinical models is key to study efficacy and safety.”
BackgroundSelf-citationIn vivo applications and toxicities of AAV-based gene therapies in rare diseases
Zhao, Q., Peng, H., Ma, Y., Yuan, H., & Jiang, H. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03893-z · Cited by 33
“The inflammatory response to AAV is dominated by CD 8+ T cells, highlighting the role of T-cell populations in hepatotoxicity [81].”
Current Landscape and Emerging Opportunities of Gene Therapy with Non-viral Episomal Vectors
Khan, S. U., Khan, M. U., Khan, M. I., Kalsoom, F., & Zahra, A. (2022) · Current Gene Therapy · doi:10.2174/1566523222666221004100858 · Cited by 27
Abouzeid, H. A., Kassem, L. M. H., Liu, X., & Abuelhana, A. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100918 · Cited by 51
Coroadinha, A. S. (2023) · Cells · doi:10.3390/cells12050732 · Cited by 27
“This exposes the AAV genome to cGas, IFI16, and AIM2, resulting in IRF3-STING dependent interferon responses and NF-kB-dependent inflammatory responses.”
BackgroundInfluentialTherapeutic advances in neural regeneration for Huntington's disease
D’Egidio, F., Castelli, V., Lombardozzi, G., Ammannito, F., Cimini, A., & d’Angelo, M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.390969 · Cited by 27
“Lentivirus and adeno-associated viruses (AAVs), chosen as vectors, are micro-injected in the specific site of interest inducing the transformation of a certain percentage of astrocytes (Verdera et al., 2020; Muhuri et al., 2021).”
BackgroundAAV-Based Gene Therapy: Opportunities, Risks, and Scale-Up Strategies
Moldavskii, D., Gilazieva, Z., Fattakhova, А. N., Solovyeva, V. V., Issa, S. S., Sufianov, A. A., Суфианова, Г. З., & Rizvanov, A. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178282 · Cited by 28
“…at the moment, for overcoming the immune response, such as using EDTA to block complement activation, developing new serotypes, and other methods to reduce antibody levels and evade them, including the use of various immunosuppressants and changes in administration methods and routes [61–64].”
Viral gene therapy for paediatric neurological diseases: progress to clinical reality
Privolizzi, R., Chu, W. S., Tijani, M., & Ng, J. (2021) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14885 · Cited by 21
“These patients were at the older end of the age cut-off and lower range of normal body weight.(36,37)”
BackgroundRevolution of AAV in Drug Discovery: From Delivery System to Clinical Application
Yin, L., He, H., Zhang, H., Shang, Y., Fu, C., Wu, S., & Jin, T. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70447 · Cited by 27
“The innate immune system has a critical function for mediating the initial vector response and priming the adaptive immune system [84].”
Chen, M., Kim, B., Jarvis, M., Fleury, S., Deng, S., Nouraein, S., Butler, S. S., Lee, S., Chambers, C., Hodges, H. C., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00371-0 · Cited by 20
“On the other hand, simply increasing the dose of AAV at the first administration may lead to vector toxicity [26], an immune response against both vector [27] and transgene [28], and potential side effects from overexpression of the transgene [29].”
BackgroundYao, J., Atasheva, S., Wagner, N. J., Paolo, N. C. D., Stewart, P. L., & Shayakhmetov, D. M. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.023 · Cited by 23
“…including conditioning of patients with inhibitors of key proin fl ammatory IL-1-and/or IL-6-dependent pathways, 53,54 modi fi - cation of DNA 55 and RNA 56 in viral and non-viral delivery platforms to reduce innate immune activation, and modi fi cation of viral capsids to reduce their…”
InfluentialStrategies for enhanced gene delivery to the central nervous system
Gao, Z. (2024) · Nanoscale Advances · doi:10.1039/d3na01125a · Cited by 29
The AAV2.7m8 capsid packages a higher degree of heterogeneous vector genomes than AAV2
Cui, M., Su, Q., Yip, M., McGowan, J., Punzo, C., Gao, G., & Tai, P. W. L. (2024) · Gene Therapy · doi:10.1038/s41434-024-00477-7 · Cited by 20
“It remains unknown whether truncated genomes can stimulate innate immune responses, such as TLR9 activation through the detection of unmethylated CpG dinucleotides [52, 53], unfolded protein responses [54], or DNA/ RNA sensing mechanisms [55].”
Self-citationThe intersection of vector biology, gene therapy, and hemophilia
Lisowski, L., Staber, J. M. R., Wright, J. F., & Valentino, L. A. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12586 · Cited by 19
Narváez-Pérez, L. F., Paz‐Bermúdez, F. J., Ávalos‐Fuentes, J. A., Campos‐Romo, A., Florán, B., & Segovia, J. (2023) · Gene Therapy · doi:10.1038/s41434-023-00414-0 · Cited by 22
“However, using viral vectors in some of these protocols may cause the integration of transgenes into the host genome, which may induce mutagenesis or activate the host immune response limiting the effectivity [17, 18].”
BackgroundNotarte, K. I., Catahay, J. A., Macasaet, R., Liu, J., Velasco, J. V., Peligro, P. J., Vallo, J., Goldrich, N., Lahoti, L., Zhou, J., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29305 · Cited by 21
“37 Complement activation can lead to the formation of complement protein complexes and the release of pro ‐ inflammatory molecules, contributing to an immune response against the AAV vector.”
BackgroundShort-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy
Lee, S., Lee, Y. J., Kong, J., Ryu, H. W., Shim, Y., Han, J. Y., Woo, H., Kim, S. Y., Cho, A., Lim, B. C., et al. (2022) · Brain and Development · doi:10.1016/j.braindev.2021.12.006 · Cited by 20
Neutralizing Antibodies: Role in Immune Response and Viral Vector Based Gene Therapy
Tsaregorodtseva, T. S., Gubaidullina, A. A., Kayumova, B. R., Shaimardanova, A. A., Issa, S. S., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., & Rizvanov, A. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115224 · Cited by 20
“Studies on mice deficient in CR1/2 or C3 (complement proteins) revealed a reduced ability to mount a humoral response to AAV compared to mice previously infected with wild-type AAV, emphasizing the complement system’s role in generating AAV-specific antibodies [104].”
InfluentialKitawi, R. C., Ledger, S., Kelleher, A. D., & Ahlenstiel, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052771 · Cited by 24
“Various strategies are being applied to overcome capsid immunity, complement fixation and AAV genome sensing [164,165].”
MethodThrombotic Microangiopathy as an Emerging Complication of Viral Vector–Based Gene Therapy
Schwotzer, N., Sissy, C. E., Desguerre, I., Frémeaux‐Bacchi, V., Servais, L., & Fakhouri, F. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.04.024 · Cited by 22
“…to restrict AAV transduction to target cells, 10,24 (ii) a decreased recognition by Toll-like receptors in endosomes (via depletion of the vector genome of CpG sites, or insertion of Toll-like receptors inhibitory sequences 20 ), 25 and (iii) the evasion from preexisting neutralizing antibodies.”
BackgroundDelivery of DNA-Based Therapeutics for Treatment of Chronic Diseases
Sussman, C., Liberatore, R. A., & Drozdz, M. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040535 · Cited by 20
“With immunity proven to play a fundamental role in efficiency of treatment, methods to improve AAV technology to avoid such responses are currently being investigated [47,48].”
BackgroundIdentifying Viral Vector Characteristics by Nanopore Sensing
Tsutsui, M., Wada, M., Arima, A., Tsunekawa, Y., Sasaki, T., Sakamoto, K., Yokota, K., Baba, Y., Kawai, T., & Okada, T. (2024) · ACS Nano · doi:10.1021/acsnano.4c01888 · Cited by 20
MicroRNA137-loaded lipid nanoparticles regulate synaptic proteins in the prefrontal cortex
Palumbo, M., Gautam, M., Sonneborn, A., Kim, K., Wilmarth, P. A., Reddy, A. P., Shi, X., Marks, D. L., Sahay, G., Abbas, A. I., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.08.016 · Cited by 19
Bioinspired and Biomimetic Gene Delivery Systems
Ho, M. T., Barrett, A., Wang, Y., & Hu, Q. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00725 · Cited by 17
Macdonald, J., Marx, J., & Büning, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.169 · Cited by 18
“67 By nature, a portfolio of serotypes and variants are available, differing in their host–vector interaction.”
Gene therapy and genome editing for type I glycogen storage diseases
CHOU, J. Y., & Mansfield, B. C. (2023) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1167091 · Cited by 20
“Strategies to minimize the immunological responses in clinical rAAV gene therapy have been extensively reviewed (Verdera et al., 2020; Muhuri et al., 2021; Weber, 2021).”
BackgroundLu, M., Lee, Z., & Hu, W. (2024) · Biotechnology Progress · doi:10.1002/btpr.3428 · Cited by 18
“45,46 Triple transfection also introduced Ad helper genes to cells.”
BackgroundIon channel traffic jams: the significance of trafficking deficiency in long QT syndrome
Mondéjar‐Parreño, G., Moreno-Manuel, A. I., Robles, J. M. R., & Jalife, J. (2025) · Cell Discovery · doi:10.1038/s41421-024-00738-0 · Cited by 16
“It is necessary to modify the viral capsids of AAVs to enhance their tissue-speci fi c tropism while reducing off-target effects in other tissues 247 .”
Egorova, T. V., Starikova, A. V., & Polikarpova, A. V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111492 · Cited by 20
Current Advances in Adeno-Associated Virus-Mediated Gene Therapy to Prevent Acquired Hearing Loss
Wu, F., Sambamurti, K., & Sha, S. (2022) · Journal of the Association for Research in Otolaryngology · doi:10.1007/s10162-022-00866-y · Cited by 16
“The body’s reaction to rAAV includes innate and acquired immunity [65, 66].”
BackgroundThe Question of HIV Vaccine: Why Is a Solution Not Yet Available?
Libera, M., Caputo, V., Laterza, G., Moudoud, L., Soggiù, A., Bonizzi, L., & Diotti, R. A. (2024) · Journal of Immunology Research · doi:10.1155/2024/2147912 · Cited by 14
“AAVs have demonstrated lower immunogenicity than other viral vector platforms, although they retain the potential to elicit a dose-dependent immune response [154].”
BackgroundExcoffon, K. J. D. A., Smith, M. D., Falese, L., Schulingkamp, R. J., Lin, S., Mahankali, M., Narayan, P., Glatfelter, M. R., Limberis, M. P., Yuen, E., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.064 · Cited by 14
“5T) 31,32 and other AAV serotypes, 45,46 nebulized delivery of SP-101 generated binding and neutralizing Ab responses but little cellular response to the capsid.”
Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing
Xu, Y., Bai, X., Lin, J., Lu, K., Weng, S., Wu, Y., Liu, S., Li, H., Wu, Z., Chen, G., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101420 · Cited by 15
Kastner, A. L., Marx, A., Dimitrova, M., Abreu-Mota, T., Ertuna, Y. I., Bonilla, W. V., Stauffer, K., Künzli, M., Wagner, I., Kreutzfeldt, M., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.11.021 · Cited by 10
Wu, F., He, W., Xiao, Y., Wu, Q., Zhang, Q., Zhang, T., Xu, L., & Pang, X. (2025) · Advanced Science · doi:10.1002/advs.202408397 · Cited by 17
What Can RNA-Based Therapy Do for Monogenic Diseases?
Clarke, L. A., & Amaral, M. D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010260 · Cited by 14
“The adeno-associated virus (AAV) vectors which have emerged as the most promising tools for delivering in vivo gene therapy are subject to both innate and adaptive immune responses [49] and getting the viral DNA into the nucleus for integration, as well as posing risks of insertional mutagenesis, presents further tech…”
BackgroundHuerta, C. T., Voza, F. A., Ortiz, Y. Y., Liu, Z., & Velazquez, O. C. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1236345 · Cited by 13
“Although viral vectors have been used in previous clinical applications, adverse immune reactions can occur with their use and impede the stability of gene expression (40, 41).”
BackgroundKashiwakura, Y., Endo, K., Ugajin, A., Kikuchi, T., Hishikawa, S., Nakamura, H., Katakai, Y., Baatartsogt, N., Hiramoto, T., Hayakawa, M., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.016 · Cited by 12
“The host immune response to AAV vectors is important for long-term stable gene expression.(32) In addition to the activation of cytotoxic T lymphocyte-mediated responses, the recognition of AAV vectors by innate immunity has recently been associated with attenuated therapeutic efficacy and adverse reactions.”
BackgroundGenome length determination in adeno-associated virus vectors with mass photometry
Hiemenz, C., Baumeister, N., Helbig, C., Hawe, A., Babutzka, S., Michalakis, S., Frieß, W., & Menzen, T. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101162 · Cited by 12
“5,6 In rAAVs used for gene therapy, the rep and cap genes are replaced by the respective therapeutic gene expression cassette.”
MethodGene Therapy: Will the Promise of Optimizing Lung Allografts Become Reality?
Gao, Q., DeLaura, I. F., Anwar, I. J., Kesseli, S. J., Kahan, R., Abraham, N., Asokan, A., Barbas, A. S., & Hartwig, M. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931524 · Cited by 11
“First, transplant patients are immunosuppressed, and it is hypothesized that innate immunity and subsequent immune activation against gene therapy vectors or foreign protein products can reduce therapeutic efficacy (9).”
BackgroundSimmons, E. M., Wen, Y., Li, J., Qian, Y., Wong, L. C., Konrad, R. J., & Bivi, N. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113397 · Cited by 11
Jarvi, N. L., Hofman, K., Venkatesh, A., Gorecki, E., & Balu‐Iyer, S. V. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.09.006 · Cited by 10
Zhang, Y., Zhu, Z., Li, Z., Feng, J., Long, J., Deng, Y., Ahmed, W., Khan, A. A., Huang, S., Fu, Q., et al. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01296-4 · Cited by 10
“AAV vectors do not integrate the target gene into the genome, showing excellent biosecurity [47–49].”
BackgroundIroanya, G. I., Subramanyam, P. N., Wells, K. D., & Green, J. A. (2025) · Human Gene Therapy · doi:10.1177/10430342251378524 · Cited by 11
Minno, G. D., Miesbach, W., Castaman, G., & Peyvandi, F. (2024) · Haematologica · doi:10.3324/haematol.2023.284622 · Cited by 21
Lin, Y., Lu, M., Cai, W., & Hu, W. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-024-13203-5 · Cited by 13
“VP1, VP2, and VP3 are encoded by the cap gene, which form the capsid that encapsidates the viral genome to form the virus particle (Maurer and Weitz-man 2020; Muhuri et al. 2021).”
Alakhras, N. S., Moreland, C. A., Wong, L. C., Raut, P., Kamalakaran, S., Wen, Y., Siegel, R. W., & Malherbe, L. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1354055 · Cited by 10
“Despite the clinical promise, AAV immunogenicity has imposed a challenge to AAV clinical success (1, 2).”
BackgroundTruncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00573-1 · Cited by 11
Kang, M. H., Thomas, S. P., Westley, C., Blouin, T., Xu, L., Chan, Y., Lisk, E., Allen, S., Vadivel, A., Nangle, K., et al. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0247oc · Cited by 9
Gene therapy for epilepsy: An emerging, promising approach for a serious neurological disorder
Ledri, M., & Kokaia, M. (2025) · Journal of Internal Medicine · doi:10.1111/joim.70059 · Cited by 15
“Pre-clinical and clinical studies have found that AAV vectors elicit a weaker immune response compared to other viral vectors such as lentiviruses (LVs) or herpes simplex viruses [5].”
Duchenne muscular dystrophy treatment with lentiviral vector containing mini‐dystrophin gene in vivo
Wang, X., Zhu, Y., Liu, T., Zhou, L., Fu, Y., Zhao, J., Li, Y., Zheng, Y., Yang, X., Di, X., et al. (2024) · MedComm · doi:10.1002/mco2.423 · Cited by 10
“The AAV vector is a commonly used vector in DMD gene therapy, 21 yet immunogenicities, preexisting serum antibodies, 22 and low packaging capacity still hamper their clinical applications.”
BackgroundYuan, L., Ling, C., Shoti, J., Yang, H., Nath, A., Keeler, G. D., Qing, K., & Srivastava, A. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102196 · Cited by 11
“It is known that AAV capsid binds to Toll-like receptor 2 (TLR2) at the cell surface, 78 and TLR2 activation has been shown to increase the phosphorylation of extracellular signal-regulated kinase (ERK).”
Sword, J., Fomitcheva, I. V., & Kirov, S. A. (2024) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x241257887 · Cited by 10
“78,79 Yet, while some studies showed no adverse effect of AAV introduction to the brain, 80,81 others reported AAV-induced astro-glial and microglial reactivity suggestive of a mild inflammatory reaction but without neuronal loss.”
High ionic strength vector formulations enhance gene transfer to airway epithelia
Cooney, A. L., Loza, L. M., Najdawi, K., Brommel, C. M., McCray, P. B., & Sinn, P. L. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae640 · Cited by 10
“Transiently blocking immune function at the time delivery, capsid evolution, PEGylation, and serotype switching are strategies to head-off these obstacles ( 41 ,42 ).”
BackgroundLiu, M., Cook, E., Dai, Y., Ehlert, E., du Plessis, F., Lubelski, J., Sleczka, B. G., Shipkova, P. A., Li, Z., Gamse, J. T., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101411 · Cited by 9
Fuchs, S. P., Mondragon, P. G., Zabizhin, R., Tomer, S., Wang, L., Cook, E., Dudley, D. M., Weisgrau, K. L., Furlott, J. R., Coonen, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63970-6 · Cited by 10
“…of Treg epitopes into the coding sequence of the transgene (induction of T cell tolerance); liver-directed AAV gene transfer (liver tolerance induction); oral antigen pre-exposure (mucosal tolerance induction); erythrocyte targeting of antigen (red blood cell tolerance induction) 14,24 – 26 .”
Self-citation
Metadata
- Authors
- Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2021-01-04
- Volume
- 131
- Issue
- 1
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7773343
- OpenAlex
- W3120585537
- Cited by
- 212
- References
- 172
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 59 · 2023: 30 · 2022: 28 · 2021: 11
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@UMassChan (submittedVersion)
- Funders
- National Institutes of Health (AI067497)
- National Heart, Lung, and Blood Institute (P01HL131471, R01HL097088, UG3HL147367)
- National Institute of Allergy and Infectious Diseases (R01AI132296, R33AI136007, R01AI067497, R01AI128358, R37AI067497, P01AI100263, R01AI141181, U19AI149646, R56AI067497)
- National Institute of Neurological Disorders and Stroke (R01NS076991)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus vectors, recombinant adeno-associated virus, innate immunity, immune evasion, gene therapy vectors, host immune response, in vivo gene therapy, immunogenicity
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Humans, Immunity, Innate, Genetic Therapy, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.